Galactose clearance (first-order) includes a blood-flow component. t A feature of the test. GEC = Galactose elimination capacity; APBT = aminopyrine breath test; ICG~indocyanine green clearance; MEGX = monoethylglycinexylidide production from lignocaine; AK BR~arterial blood ketone body ratio.
It is neither realistic nor helpful to expect a single investigation to evaluate liver function given the diversity of circumstances in which such tests are performed. For example, the test may be requested as an initial attempt to diagnose liver disease or to exclude hepatic complications. It may also be applied to establishing the extent of recognized liver dysfunction, to ascertain the progression of liver disease or to assess the success of specific therapies in acute and chronic hepatic disease. Finally, it may be used to evaluate progress after hepatobiliary surgery (ranging from cholecystectomy to transplantation) and to screen for liver damage during therapy with known or suspected hepatotoxic drugs. The problems of assessing function in this range of circumstances are compounded by the heterogeneity in the types of cell the liver comprises (including parenchymal, endothelial, epithelial, Kupffer and Ito cells) and the diverse functions they perform. Included among these are the synthesis of lipids, proteins and carbohydrates and the degradation of endogenous compounds and xenobiotics, the synthesis and excretion of biliary components and collagen precursors, the storage of glycogen, lipids, iron, copper and vitamin A, the regulation of hepatic blood flow and the phagocytosis of microorganisms and release of cytokines.
Sherlock has suggested that the multiple functions of the liver are exceeded only by the biochemical methods designed to test them.' Broadly, these tests may be divided into two groups: the standard 'liver function' tests (LFTs) and a range of newer tests that have greater diagnostic power, or assess prognosis or specific aspects of functional capacity. The battery of LFTs available in most clinical biochemistry laboratories attempts to evaluate a range of key liver functions and include measurements in Correspondence: Dr J M Tredge.
This article was prepared at the invitation of the Clinical Laboratory Investigations Standing Committee of the Association of Clinical Biochemists but the views expressed are those of the authors. serum of total bilirubin, protein and albumin concentrations and aminotransferase, alkaline phosphatase (ALP) and y-glutamyltranspeptidase (y-GT) enzyme activities.? Used now for more than 30 years, a major deficiency of these tests is that they do not assess how well the liver is performing its diverse functions at the time they are measured being essentially indicators of liver dysfunction over the previous days and weeks. The prothrombin time is a valuable adjunct and provides a more immediate assessment of liver synthetic function because of the short half-life of its component coagulation factors. The sensitivity of LFTs varies with aetiology':" and it should also be emphasized that their specificity is based on reference ranges derived from healthy populations? The greatest deficiency of LFTs is that they are not diagnostic of liver disease or dysfunction in more than its broadest sense, and cannot be used in isolation to make a diagnosis. However, serial measurement is valuable in assessing the extent and progression of liver disease, either acutely (e.g. AST and bilirubin in liver failure) or chronically (e.g. albumin and bilirubin in the progression of primary biliary cirrhosis), The tests are also cheap, readily available and understood by general practitioner and specialist alike. When available to the clinician who is making an examination, they are likely to direct his questions and subsequent investigations more cost-effectively.
After detecting liver dysfunction, subsequent investigations may be required including imaging techniques such as, ultrasonography, computed tomography, magnetic resonance and endoscopic cholangiography or liver biopsy. These tests can provide not only a precise diagnosis but also an assessment of the extent of liver dysfunction, allowing specific treatment options to be decided. The new liver function tests have emerged as the range of treatments for liver dysfunction developed in response to a growing understanding of the underlying disease processes; they include anti-viral and antifibrotic drugs, gene therapy and liver transplantation. This article reviews two major classes of test: (a) those which reflect the function of the liver or its component parts such as hepatocellular mass or liver blood flow; and (b) those which detect underlying hepatic dysfunction.
TESTS OF HEPATIC FUNCTION AND DYSFUNCTION
Tests of hepatocellular activity (quantitative liver function tests) Ideally quantitative assessment of functional hepatic mass should cover the range from normal function to a threshold incompatible with survival. The test should also be sensitive to variations in function occurring naturally or in response to drugs," and should be unaffected by confounding factors such as extrahepatic metabolism, dietary intake, administered drugs and physical variables such as posture, gender and blood flow. Finally, the tests should have some prognostic significance so that the best time for therapeutic interventions such as liver transplantation can be judged. Not surprisingly, a single test fulfilling these requirements across a broad range of liver diseases of different pathogeneses remains the hepatologist's dream. The following five tests (Table I) have been applied in a broad range of circumstances and found to satisfy many of the above criteria. Although the first three tests are not new, they are continually reassessed in new applications. However, they are complex, requiring multiple blood samples or the administration and measurement of isotopes making them impractical other than in specialist centres, although simpler protocols are emerging which may improve this. 7 ,8 Galactose elimination capacity (GEC) measures the zero-order clearance of galactose during its hepatic phosphorylation? and values below 2 mg/kgjmin are incompatible with survival. Recent studies have demonstrated its ability to predict survival in patients with late stage primary biliary cirrhosis (PBC) lO its value, particularly in chronic liver disease where portal hypertension and oesophageal varices (indicators of hepatic shunting) contribute significantly to mortality." ICG was an independent predictor for the progression of viral or alcoholic cirrhosis to hepatocellular carcinoma (in nearly 800 patientsj.!? was a prognostic factor in patients with cirrhosis" and correlated with the signal intensity for hyperintense globus pallidus on magnetic resonance imaging scans in patients with cirrhosis awaiting liver transplantation. 19 It was also shown to be more valuable than GEC, APBT or standard liver function tests for discriminating disease severity in cirrhotic patients.P Methodological inconsistencies in test results can be overcome using high-performance liquid chromatography (HPLC) instead of spectrophotometric analysis." Monoethylglycinexylidide formation test (MEG X) ( Fig. 1) is also a CYP450-dependent test," but catalysis is by several isoenzymes including CYP3A and CYP2B 1 which are abundant in, but not exclusive to, liver and which show a gender difference in activity.n-26 A major advantage of the test is its simplicity, with a single blood sample required 15-30min after bolus administration of lignocaine. The test was a reliable predictor of l-year survival in both adult?" and paediatric" patients with chronic liver disease. Higher results in liver transplant donors were also associated with a more favourable outcome in recipients of these liver grafts," although these data are controversial.t"-" Recently, MEGX (monoethylglycinexylidide) formation was shown to be inferior to GEC or APBT for discriminating disease severity in patients with liver disease.F However, MEGX has advantages over the Child-Pugh score (see later) in assessing prognosis in patients with alcoholic or viral cirrhosis. 33 Arterial blood ketone body ratio (AKBR) (the ratio of acetoacetate: 3-hydroxybutyrate in arterial blood) was proposed as an indicator of hepatic mitochondrial function and hepatic redox state by Ozawa and colleagues in 1983. 34 Reductions in AKBR are associated with increased morbidity and mortality in patients undergoing hepatic surgery, those who died showing consistently low values « 0-4) for more than 5 consecutive days." There is also evidence that the AKBR may have prognostic value for patients with fulminant hepatic failure" and the test has been widely applied in the living-related
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donor liver transplant programme at Kyoto University Hospital in Japan with claimed success.F The assay method is relatively simple and a dedicated spectrophotometer and diagnostic kit are available (Genzyme Diagnostics, West Mailing, Kent, UK). A wider appraisal of the test is required to judge whether it is a valuable liver function test, particularly in view of the known extrahepatic metabolism of the two analytes.P Two further tests which have not met initial expectations are serum bile acid measurements and the caffeine clearance test. Serum bile acid measurements two hours after meals, have shown a high specificity for detecting liver dysfunction, but may offer little advantage to conventional aminotransferase activities for detecting mild disease." Caffeine clearance depends on repeated measurements of caffeine in blood, saliva or of CO 2 in exhaled air (after isotope administrationj." The drug's demethylation, catalysed by CYPlA2, shows dose-dependent pharmacokinetics" and may be affected by administered drugs e.g., oral contraceptive steroids and by cigarette smoking. Values in normal volunteers may vary fourfold.F consequently the test is only valuable if applied sequentially to individuals whose dietary caffeine intake is controlled and whose smoking habits and drug history are constant.
A test with potential value needing verification is hepatic functional imaging with a 99mtechnetium-labelled ligand of the asialoglycoprotein receptor (where internalization of galactose-terminated glycoproteins normally occurs'"). Based on the correlation between asialoglycoprotein receptor concentrations and the severity of liver dysfunction in patients with chronic and acute liver disease (assessed using conventional markers and scoring systems), the test has been proposed as a sensitive measure of functioning hepatic mass."
Tests of hepatic dysfunction Hepatocellular damage Glutathione S-transferase a-isoenzyme (GST-rx.) concentrations are emerging as an alternative to the aminotransferases for assessing hepatocellular damage. GST-rx. has advantages in terms of specificity and sensitivity compared with lactate, sorbitol and isocitrate dehydrogenase activities'f and is relatively easy to measure. GST-rx. is one of the family of glutathione transferase enzymes which catalyse detoxification reactions between reduced glutathione and electrophiles or hydrogen peroxide." The highest concentrations of GST-0( (about 5% of cytosolic protein) are found in liver, with lower concentrations in adrenal, testis and kidney. Unlike AST, which is concentrated in periportal hepatocytes, GST-O( is evenly distributed across the liver acinus and is therefore released in all types of hepatocyte injury. It has a half-life in blood of 90 min, and thus provides a sensitive and rapidly responding marker of liver injury and subsequent clearance unmatched by the aminotransferases, the halflives of which exceed 17 h. 47 Plasma GST-O( (but not AST) increased in patients undergoing prolonged surgery under halothane, but not isoflurane, anaesthesia." Plasma GST-O( was also shown to be a more sensitive early indicator of liver damage than alanine aminotransferase (ALT) activity in paracetamol overdosage and detected a discrete late phase of liver damage in patients developing severe hepatotoxicity.t? In liver transplant recipients, GST-0( was found more valuable than AST in detecting early rejection episodes postoperatively because of its shorter half life. 47 It may also be more sensitive than AST for detecting transplant rejection and less susceptible to the confounding effects of infection (Gonde CE, Tredger JM, Williams R, in preparation). The enzyme-linked immunoassay (ELISA) for GST-O( (Hepkit, Biotrin UK, Surrey, UK) is practical for most laboratories and a recent improvement in calibration stability removes the need for full calibration curves with each assay.
Cholestasis
Glutathione transferase-pi isoenzyme (GST-pi), unlike GST-O(, is localized in the biliary epithelium'" and has been proposed as a marker of biliary epithelial damage. GST-pi can be measured by ELISA in bile and in plasma, but in the latter case its specificity may be compromised by GST-pi released from pulmonary and oral carcinomas.P>' !!-Bilirubin. Normally over 90% of bilirubin in plasma is in the unconjugated forrn.? In hepatocellular or cholestatic liver disease, increases occur in the concentrations of glucuronide, glucose and xylose ester conjugates of bilirubin which are formed in the liver. It is now recognized that a third bilirubin fraction exists which is irreversibly (presumably covalently) bound to albumin. 53 This bilirubin-protein conjugate, often called A-bilirubin, is present in serum in the disorders associated with increased serum conjugated bilirubin concentrations but Ann Clin Biochem 1997: 34 has a significantly longer half-life." A number of HPLC methods have been used to quantitate the various bilirubin fractions but these are not particularly suitable for routine use. 55.56 The Ektachem (Johnson & Johnson, Amersham, UK) analyser allows the indirect measurement of the bilirubin-protein conjugates by retaining these on a size-exclusion layer and quantitating the non-protein bound forms. Subtraction of the latter from a measurement of total bilirubin produces the !!-bilirubin concentration.f It is not clear whether !!-bilirubin measurement provides any significant advantage over total and conjugated bilirubin estimation but it has been claimed that an increase in the conjugated fraction without a concomitant rise in the !!bilirubin is a poor prognostic sign in patients with liver disease. 54,58
Carbohydrate antigen /9-9 (CA/9-9) is the sialylated Lewis' blood group structure. 59 Some of the highest CA19-9 levels (10000-50000 lUI L) have been obtained in patients with acute cholangitis secondary to gallstones.s" although the test is generally considered to be a marker of pancreatic or colorectal carcinoma"! and has high sensitivity for biliary cancer. Increased serum CA19-9 has been reported in 47% of patients with cirrhosis and in other benign liver diseases.P The elevation of CA 19-9 in cholangitis has been used for the monitoring of the disease process in primary sclerosing cholangitis (PSC)63 as the serum CA 19-9 concentration varies with the disease severity. In combination with carcinoembryonic antigen, it may be useful in the detection of cholangiocarcinoma in patients with PSC. As the serum concentration of the carbohydrate antigens reflects both production and clearance, cholestasis impairs biliary clearance resulting in increased serum levels. This must be taken into account when using CA 19-9 as a tumour marker but may prove useful in itself in cholestatic diseases, particularly cholangitis.
Synthetic function
Most coagulation factors are synthesized exclusively in the liver and several have short halflives (e.g. 2-5 h for factor VII). Consequently, the measurement of coagulation factors in plasma provides a valuable indication of immediate hepatic function, particularly where their consumption is enhanced (e.g. in liver damage induced by drugs, viral infections and alcoholic hepatitis) or where synthesis may be impaired (e.g. after liver transplantation).
Prothromhin time (PT)
is widely used and is standardized as the International Normalized Ratio (INR) to values in control plasma. The PT reflects the activity of coagulation factors of the extrinsic (tissue-factor) pathway, particularly Factors II, V, VII and X and their ability to form fibrin from fibrinogen under the influence of thrombin. A prolongation of PT, alone or in combination with other abnormal LFTs, is valuable for detecting deteriorating liver function in alcoholic hepatitis'" and end-stage PBC 65 and for predicting prognosis in fulminant hepatic failure following paracetamol overdose 66, 67 or hepatitis viral infections.s'' The activated partial thromboplastin time (APTT) measures coagulation via the intrinsic (i.e. contact-activated) pathway. Although APTT is often less valuable than INR for diagnosing liver dysfunction, because of its greater susceptibility to interference by heparin, low values at 8 days after liver transplantation were associated with an adverse outcome during the following 6 months."
Factors V and VII
Of the single coagulation factors, factor V and factor VII measurements are the two most used in evaluating liver function. Reductions in circulating factor V to below 10-20% of normal have been useful in assessing prognosis in fulminant hepatic failure due to viral infections.s? and for selecting patients for liver transplantation. Proposed benefits in defining prognosis in acute alcoholic hepatitis;" and outcome after liver transplantation71 require confirmation in larger series. The use of factor VII for defining non-function of the newly grafted liver 71.72 is a valuable observation requiring confirmation but corroborates the value of the test demonstrated in cirrhotic patients as an independent predictor of survival."
Fibrosis
Fibrosis occurs as liver disease progresses, when control of collagen synthesis becomes deranged and increased collagen deposition occurs. Attempts to quantify the extent of fibrosis based on measurements of the types, precursors and breakdown-products of collagen or other fibrous tissue components have proved largely unrewarding but they have specific benefit as described below. Type III and type I collagen predominate in early and late cirrhosis, respectively." The precursor to type III collagen,
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procollagen type III peptide (PIIINP) can be measured in serum by immunoassays directed against the N-terminal region." Many studies have now been carried out on the use of PIIINP measurements in liver disease" some of which are shown in Table 2 . 77-99 Collazoz and Diaz lOO in a recent study of patients with various liver diseases could not identify any single independent determinant of elevated PIIINP results, which suggests multi-factorial causes. The apparent lack of specificity for fibrosis may be due to a number of factors including alterations in the biliary excretion of PIIINP.101 Most significantly there is some evidence that the propeptide can be retained in mature collagen fibrils and is released on degradation rather than during synthesis of collagen. 102 Prolyl hydroxylase is the rate limiting enzyme in the synthesis of collagen and its biochemistry and physiology has been reviewed by Pihlajaniemi et al. 103 Prolyl hydroxylase has been studied in various liver diseases ( Table 2) 104-108 and has been shown to be elevated in patients with alcoholic liver disease,104,105 hepatitis,'?" cholestasis''" and hepatocellular damage l07,108 with a good correlation with histologically assessed hepatic fibrosis.104--106
Laminin is a major non-collagenous glycoprotein of basement membranes and is co-distributed in the liver with type IV collagen.?" The concentration of laminin in serum is believed to reflect the metabolism of basement membranes and has been reported to correlate with the extent of hepatic fibrosis but is also elevated in portal hypertension (Table 2) . [109] [110] [111] [112] [113] Fibronectin is a mediator of cellular adhesion to collagens, fibrin and heparin. In plasma it is a potent chemoattractant involved in the organization of thrombi, whilst in the liver it is found in all extracellular compartments including the basement membrane.I" Although fibronectin in plasma has been shown to be increased in fibrotic alcoholic liver disease the discriminatory power for fibrosis is pOOr. 88.114 Type IV collagen is a major component of basement membranes and is structurally distinct from the fibrillar collagens. Antigens of the 75 domain can be measured in serum and initial studies have shown a superiority over other markers for discriminating subjects with fibrotic liver disease in a population with chronic viral hepatitis infections.Fv"
Most of the aforementioned compounds are putative markers of collagen formation and deposition. In chronic liver disease collagen degradation is also increased, with a concomitant increase in the enzymes involved in collagen breakdown, e.g. collagenase. Any collagenase released into plasma will be inhibited by the circulating anti-proteases cx-2-macroglobulin, tissue inhibitor of metalloproteinase (TIMP) and PI anti-collagenase. Recently an assay for serum collagenase after dissociation of the inhibitor complexes has been described. I IS Using this assay, Murawaki et al. l l b have demonstrated that the serum collagenase concentration is related more to the TIMP concentraton than to liver collagenase activity. A reliable marker of collagen degradation is therefore still not available.
The PGA index is a composite score incorporating the prothrombin time, y-GT activity and cxapolipoprotein concentrations. While demonstrating a greater sensitivity than PIIINP alone for detecting of hepatic fibrosis in patients with alcoholic liver disease,"? there was no comparable benefit in patients with PBC or chronic hepatitis B.m
Liver blood flow
Doppler flow ultrasonography is increasingly used for evaluating the integrity of the portal venous or hepatic arterial blood supply to the liver after liver transplantation but the quantitation of hepatic blood flow continues to present a technical and practical challenge. Its measurement is valuable both where there is a suspicion Ann Clin Biochem 1997: 34 of thrombosis (e.g. the Budd-Chiari syndrome or hepatic artery thrombosis after liver transplantation) and where hepatic shunting and portal hypertension occur in association with chronic liver disease. It is rarely possible to cannulate both the hepatic portal vein and hepatic vein to allow direct measurements and the most feasible alternatives are those measuring the clearance of indocyanine green, IS galactose!" or sorbitol. 120 The two former tests are allied to the use of these compounds in determining hepatocellular activity as described above but require constant intravenous infusions of the substrates. Sorbitol clearance may allow more representative measurements of blood flow than galactose because of its greater hepatic clearance'-" and may be less susceptible to methodological difficulties than indocyanine green" but may still be unsuitable for estimating the intrahepatic shunting of blood flOW l21 in patients with chronic liver disease. A recent innovation has been the application of dynamic computer analysis and thermodilution of indocyanine green in the Pulsion COLD (circulation, oxygenation, liver function, diagnosis) system.P? This allows a haemodynamic assessment far exceeding that which is possible using simpler indocyanine green techniques, but the highly invasive and technically demanding nature of these investigations limit their application to research studies in specialist intensive care units.
Tests of liver graft function/dysfunction
Liver biopsy provides the most comprehensive assessment of graft integrity after transplantation but it may not be feasible if clotting times are prolonged. Alternative less invasive tests have been sought, particularly in the detection of primary graft non-function and in the early diagnosis of acute graft rejection. In the former, occurring in 2-23% of graft recipients, emergency re-transplantation is required and early diagnosis is essential to maximize the time available for obtaining a replacement organ. Using the quantitative tests, reduced MEGX production 123 or indocyanine green clearances below 200 ml.jrnin 124 were suggested to predict an adverse outcome. Measurements of clotting factors may also be valuable because of their short half-life, their consumption in damaged liver and their impaired synthesis.I'<" However, in a large series of graft recipients, no reliable model could be constructed to predict long-term outcome using variables which were associated with outcome in a univariate analysis.l-" Acute liver graft rejection is characterized by histological features of vascular, biliary epithelial and parenchymal damage. The surrogate markers of rejection have therefore measured the products of such damage in serum-typically AST and bilirubin. Serological indicators shown to change during acute rejection episodes include increased nitric oxide generation 126 and hyaluronic acid 127 as markers of vascular injury and increased GST-1X 46 and the ratio of mitochondrial and cytoplasmic AST activities'-" as markers of parenchymal damage. Although marked decreases in aminopyrine breath test results'j? have been demonstrated at the time of acute rejection episodes, routine daily determinations are not a practical proposition.
Circulating levels of tumour necrosis factor (TNF) 1X,130.131 interleukin 6,130,132 C-reactive protein.'?" soluble interleukin 2 receptor, soluble CD-8 and amyloid A protein!" are other putative markers of acute rejection episodes which have been evaluated. However, many of these tests lack specificity, being particularly affected by bacterial and cytomegaloviral infections.P" Recently, an interesting correlation was
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reported between elevated serum TNF-IX concentrations around the time of transplantation and subsequent acute rejection episodes, with corresponding elevations in interleukin 6 levels correlating with subsequent viral and bacterial infections.P? Finally, it should be emphasized that acute rejection is characteristic of inadequate immunosuppression and a useful adjunct to its diagnosis is the measurement of blood levels of the primary immunosuppressive drugs. Tacrolimus (FK506) is the first of a new generation of these agents and is now licensed for use in liver and renal graft recipients. Like cyclosporin.P' it requires routine monitoring to ensure efficacy and limit side-effects.I" Two further aspects of evaluating graft function have been the use of tests for identifying liver donors with poor hepatic function and the evaluation of the status of liver explants. The MEGX test!" ( into its preservation solution during storage. The latter have included AST, creatine kinase BB isoenzyme and purine nucleoside phosphorylase'F and hyaluronic acid 13~but their practical value is limited to altering supportive therapy as the decision to use a donor liver would not be made on the basis of these results alone.
Predicting prognosis, assessing disease progression/remission and evaluating treatment efficacy
The prediction of prognosis has become particularly important with the increasing use of liver transplantation as a final therapeutic option, but the problems differ greatly in end-stage acute or chronic disease. In fulminant (i.e. rapid-onset) hepatic failure, the aim is to identify rapidly patients who will not survive without transplantation, while avoiding wastage of a valuable resource on unnecessary grafting. In chronic liver disease, optimal timing maximizes the chance of success while minimizing loss of high-quality lifestyle (possible if transplantation is too early). In fulminant hepatic failure, deterioration may be so rapid that death may occur within the median of 3 days required to find a superurgent liver graft (UK Transplant Support Service Agency, London, UK 1995, personal communication). Consequently, early prediction of a likely adverse outcome is essential. While single tests (e.g. GEC, APBT) may be useful in predicting prognosis in fulminant hepatic failure, !3~!41 multifactorial scoring systems show a Ann cun Biochem 1997: 34 high prognostic accuracy (Table 3) .142 At King's College Hospital, London, O'Grady and colleagues'" devised separate criteria for use in liver failure due to paracetamol overdose or other causes. Alternative criteria developed in France rely on hepatic encephalopathy and marked depression of clotting factor V Ievels." At the time of admission to hospital, predictive accuracies around 80% were achieved with the former compared with 60% for the latter. 143 This suggests that further improvements, such as the use of reduced factor V cut-off values or ratios of factor V: factor VIII may be possible.':"
In chronic liver disease, several of the quantitative LFTs (see above) have been used to assess outcome with mixed success. Reports of the more successful applications in end-stage liver disease include the use of the GEC in patients with PBC,IO the APBT in cirrhotic patients." the M EGX test in both adult27J3.145 (Table 3 ) and paediatric" cirrhotics and ICG in two large cohorts of cirrhotic patients.P'?" Although single tests may be ideal for assessing responses to treatment in chronic liver diseases where specific markers of disease exist (e.g. oc-fetoprotein in hepatocellular carcinoma), scoring with multiple assessment criteria usually provides a more reliable indication of prognosis. Such systems often benefit from the inclusion of variables associated with disease complications as well as criteria specific to the disease under evaluation ( Table 4 ). For example, the Child-Pugh score (devised more than 20 years ago)146 has provided an enduring reference for assessing (Table 4 ), In PSC, a comparison of two prognostic scoring systems150.151 showed some marked differences in the rank order of the independent variables suggesting population differences and the need for further validation, In alcoholic hepatitis (where a short-term mortality between 20 and 60% has been reported 152) a discriminant function score has been devised'" which predicts mortality in 75% of cases, Observations that factor V levels also had prognostic value in a group of patients with alcoholic hepatitis?" suggest that inclusion of such parameters might enhance the power of the score,
DIAGNOSTIC TESTS
This section presents a resume of the current serological tests used in establishing the diagnosis of liver disease, While the importance of liver biopsy in differential diagnosis cannot be overemphasized, its interpretation is beyond the scope of this review. The interested reader is referred to authoritative texts describing the histological features associated with these dis-eases l53 and their characteristics.P' The tests described here are both established investigations and newer, definitive or differentially diagnostic procedures for specific diseases, The value of the standard LFTs in this process has been considered comprehensively elsewhere,2,155
Liver tumours
a-Fetoprotein (AFP) has remained the most important serological marker of primary liver tumours since it was first associated with hepatocellular carcinoma more than 30 years ago, While values elevated more than 40 times the upper limit of normal for standard immunoassays (10 Jlg/L) provide strong evidence for primary hepatocellular carcinoma in both cirrhotic and non-cirrhotic livers, intermediate levels may be associated with other hepatic disorders as well as pregnancy and some tumours of the pancreas, stomach and gall bladder.l " Using isoelectric focusing to analyse serum in this intermediate range, two isoforms of AFP were identified (AFP III and IV), These had isoelectric points more alkaline than the dominant isoform and were strongly associated with hepatocellular carcinoma (sensitivity 81%, specificity 85%), 156 Not only were such isoforms absent in 86% of patients with non-malignant hepatic disease, but in one case they appeared 19 months earlier than elevations in total AFP which predated detection of tumour on ultrasound by 5 months.P" Hepatoma-specific forms of ALP,157 y_GT 158 and des-j-carboxy prothrombin'P? are additional markers of hepatocellular carcinoma with varying prevalence in affected patients, whilst 5hydroxyindoleacetic acid (5-HIAA) is an established marker for carcinoid tumours.l'" Many tumours metastasize to the liver and therefore tumour markers for the primary tumour may be useful for assessing the development and extent of liver involvement. Discussion of such tumour markers is beyond the scope of this review and readers are directed to recent reviews on the subject. 161,162 Vitamin Bl2 is transported in the blood by the transcobalamines. Fremont et al. 163 reported that transcobalamin was higher in patients with hepatomas than in normal controls and subjects with non-malignant liver diseases.
Metabolic liver disease
The range of metabolic errors associated with liver diseases is enormously diverse and advances in only three of the more common disorders are considered here: (X-I-an titrypsin deficiency; Wilson disease; and genetic haemochromatosis. The interested reader is referred to the comprehensive review of Ishak and Sharp l64 for a discussion of other metabolic disease which involve the liver.
Alpha-I-antitrypsin (AAT) deficiency
AA T deficiency is a recognized cause of cirrhosis of the liver in early cbildhood.I'< The most common deficiency mutation, PiZZ, arises from a single point mutation and results in polymerization of AA T molecules leading to accumulation of the Z protein in the liver. 166 Up to 50% of PiZZ children have biochemical evidence of liver dysfunction and approximately 10% progress to hepatitis and cirrhosis.l?? AA T deficiency is often detected by the observation of a reduced (XI-globulin band on serum protein electrophoresis, which is confirmed by separation of the variant forms by isoelectric focusing.l'" The AAT gene is located on the long arm of chromosome 14 and has been mapped to position q31-31·2. 169 With the advent of the polymerase chain reaction (PCR), methods have been developed for the specific detection of the Z-mutation in DNA from blood, buccal scrapes and chorionic villus biopsy samples.F'"!" The ARMS method (amplification refractory muta-Ann Clin Biochem 1997: 34 tion system) permits the confirmation of the genotype in affected individuals and, using chorionic villus samples, the prenatal diagnosis of an affected fetus.174.175
Haemochromatosis
Encompassing the range of disorders characterized by massive iron sequestration in the liver, haemochromatosis leads to parenchymal damage and cirrhosis. Serum ferritin is considered to be the best index of hepatic (and total body) iron stores and major elevations (up to 15fold increases in haemochromatosis) are indicators for liver biopsy in which iron content can be assessed 176 as the definitive diagnostic criterion. Alternative liver diseases associated with increased serum ferritin concentrations (usually of a smaller magnitude) are alcoholic liver disease and autoimmune hepatitis. 155 
Wilson disease
Wilson disease has long been known to have an autosomal inheritance but the gene, assigned to chromosome 13 in 1985,177 was cloned, sequenced and associated with a copper transporting ATPase only in 1993. m , 179 It showed homology to the Menkes disease gene. ISO The identification of heterozygotes will be greatly simplified when molecular techniques are more widely applied to isolated DNA. In the interim, detection of affected individuals can be achieved with measurements of serum copper and caeruloplasmin, together with liver copper content and urinary copper excretion after penicillamine challenge. 181
Alcoholic liver disease Alcohol induced liver disease is a progressive condition beginning with fatty infiltration of the liver and hepatitis which progresses to cirrhosis in 10-20% of cases if excessive alcohol consumption is continued. Conventional tests for alcohol consumption and liver damage including mean corpuscular volume (MCV), y-GT, AST and AL T are usually used to assess patients and monitor the progression of the disease. 182 These are all relatively non-specific and are elevated in many conditions unrelated to alcohol consumption.
Within the hepatocyte, AST exists in two isoenzymic forms: cytoplasmic (c-AST) and mitochondrial (m_AST).IS3 Animal studies suggested that m-AST did not appear in the circulation until appreciable necrosis of hepatocytes occurred.l'" It was therefore proposed that m-AST may be a better indicator of the severity of hepatocyte damage than c-AST or total AST. However, in alcoholic liver disease, several groups have reported a disproportionate rise in m-AST, with the result that the m-AST/total-AST ratio is up to four times higher than in viral hepatitis or normal subjects. 183.185,186 Both the sensitivity and specificity of the ratio were higher than y-GT and glutamate dehydrogenase for alcoholic liver disease. Abstinence from alcohol normalizes the m-AST within approximately 2 weeks. The mechanism for this is unclear but it may be a consequence of alcohol induction of mitochondrial enzymes or due to interference with plasma clearance of the m-ASTI87 because the latter occurs in extrahepatic cholestasis in which serum m-AST is also elevated.!" Alternatively, it may be due to a specificity for mitochondrial damage following alcohol ingestion because perturbations in mitochondrial function have also been demonstrated using an z-keto-isocaproic acid breath test"? which showed derangements in alcoholic subjects not present in other cirrhotic patients or controls.
Stibler and Kjellin in 1976 190 detected an abnormal transferrin in the cerebrospinal fluid of 80% and in serum of 50% of individuals with alcoholic cerebellar degeneration. This was subsequently shown to be a form of transferrin lacking two to four of the terminal sialic acid residues and has been termed carbohydratedeficient transferrin (CDT). 191 The original use of isoelectric focusing for the separation of the abnormal transferrin, has been superseded by two more practical methods based on micro anion exchange chromatography193 and chromato- Viral hepatitis Viral infections represent the most common cause of acute hepatitis. The most frequent are those with the A, B, C, D, E and other 'non-ABCDE' hepatitis viruses, followed by a range focusing followed by radioirnmunoassay.P! A large number of studies have now been carried out on CDT in relation to alcohol consumption (reviewed by Stiblerj''" and in various nonalcohol related liver diseases. Initial optimism that CDT was a marker for excess alcohol consumption unrelated to the presence of liver disease!" has been tempered by subsequent observations that CDT could not be detected in alcoholics without liver disease.':" and did not correlate well with AST, ALP, and bilirubin in patients with alcoholic liver disease.'?" However, consumption of more than 60 g of alcohol a day for more than 7 days consistently causes an elevation of CDT which falls to normal over a period of several weeks abstinence. 198 The mechanism for these changes in transferrin microheterogeneity has not been elucidated but may involve decreased activity of glycoprotein glycosyltransferase due to the excess alcohol in circulation I 99.200 or a reduction in CDT receptors due to the liver damage.P' A comparison of the sensitivity of CDT with that of the most commonly used alternative tests is presented in Table 5 for alcohol-dependent subjects and in community screening programmes.F" Despite the lower sensitivity for hazardous alcohol consumption than originally hoped for, CDT measurement in serum may be a useful means of detecting alcohol abuse in patients with raised MCV and y-GT who deny excess alcohol consumption, or for assessing compliance in supposedly abstinent subjects.
Of interest in the continuing search for a marker of excess alcohol consumption which is independent of the existence of liver disease was the observation that alcohol induces a shift in serotonin metabolism from the normal end product 5-HIAA to 5-hydroxytryptophol (5-HTOL). 203 Voltaire et al. have shown that the 5-HTOL/5-HIAA ratio in urine was elevated in normal volunteers 12 h after alcohol consumption in a dose-dependent manner.P' A novel observation in Japanese alcoholic patients which requires confirmation was a greater prevalence of cirrhosis and fibrosis in homozygotes of a cytochrome P450IIE isoenzyme identified by restriction fragment length polymorphism techniques.j'" of herpes viruses. This subject has been recently reviewed in depth 206 but it is included here to identify some newer tests, as well as to summarize the current status of testing for the major viral infections ( Table 6) .
Hepatitis A (HAV) and E (HEV) are known to be enterally transmitted and there is no evidence for chronic viral carriage. In contrast, hepatitis B (HBV), C (HCV) and delta (HDV) are contracted parenterally, via sexual contact or vertically (i.e. from mother to child), although in some cases of HCV infection no definitive parenteral exposure can be found. The largest proportion of those infections previously termed 'non-A, non-B' are with HCV. The advent of RNA amplification techniques means that HCV RNA measurements can be used to detect viraemia which may persist in peripheral blood mononuclear cells despite clearance from plasma. 207 Similarly, HEV RNA has been detected by PCR methods in research studies. Hepatitis delta viral infection shows a close association with HBV, with HDV RNA particles wrapped in a HBsAg protein coat. Infection with HDV is associated with a greater risk for developing fulminant hepatitis and progressing to chronic liver disease than HBV alone, but a better response to therapy and a reduced likelihood of reinfection after transplantation.20M Most of the assays shown in Table 6 are commercially available now and many current automated Ann cu« Biochem 1997: 34 immunoassay analysers carry a wide range of these tests.
Primary biliary cirrhosis (PDC)
This progressive autoimmune-based disorder predominantly affects middle-aged women and is the most common indication for liver transplantation in the UK. 209 Definitive diagnosis is based on liver biopsy findings, but the presence of anti-mitochondrial antibodies, together with raised serum ALP and IgM concentrations is a feature in 90% of patients."? The anti-mitochondrial antibodies are directed at a number of mitochondrial membrane components including M2 (inner membrane) and M4, M8 and M9 (outer membrane). The M2 antigen has been identified as components of the 2-keto acid dehydrogenase multienzyme complex (principally the E2 component) of pyruvate and provides the greatest sensitivity for diagnosis.P? The presence of antibodies to M4 and M8 has been suggested to be associated with progressive disease, while those to M9 may indicate a benign course.I'" However, commercial assays for these antigens are not yet available.
Primary sclerosing cholangitis (PSC)
This progressive inflammatory disease of both extra-and intra-hepatic bile ducts has a male predominance and is often associated with inflammatory bowel disease. lSI Serum ALP and l'-GT concentrations are almost invariably raised, but bilirubin levels fluctuate. There are no specific serological markers of the disease, but raised serum caeruloplasmin and urinary copper concentrations and high titres of antineutrophil cytoplasmic antibodies may OCCUr. 211 Ultimately, the diagnosis is based on the results of liver biopsy and/or endoscopic retrograde cholangiopancreatography, which allow differentiation from PBC and autoimmune hepatitis. The presence of mutations in the HLA class II DR region was shown recently to increase susceptibility to PSC and may be linked to the expression of leucine at position 38 of the DR fJpolypeptide."? This mutation occurs in only about 25% of patients with PSC and other genetic or environmental associations are likely to be involved in the expression of the disease. None the less, this mutation is expressed in the floor of the peptide-binding domain of the DR molecule and this is consistent with the autoimmune or immunologically-mediated nature of the disease.
Autoimmune hepatitis
This term (now preferred to autoimmune chronic active or persistent hepatitisj-!' describes a lesion of unknown aetiology in which hepatitis frequently progresses to cirrhosis. Features of autoimmunity (e.g. a female preponderance, circulating autoantibodies and an HLA B8/ DR3 haplotype) and a responsiveness to immunosuppressive therapy are characterisic. However, diagnosis is a multifaceted and complicated process and a scoring system has recently been proposed based on serological, histological and static markers ( Table 3 ) which rationalizes the process.i" Drug-induced hepatotoxicity There are an estimated 600 drugs that induce a range of liver dysfunction as wide as that associated with natural disease and exposure to viruses and alcohol.i'" The two most important factors linking drug ingestion and hepatic damage are an awareness of the potential for causing drug-related injury and a knowledge of the lesions associated with particular drugs. Proving the association may be more difficult, but the exclusion of alternative causes may be corroborated by an improvement in symptoms after drug withdrawal. Where damage arises acutely [e.g. after paracetamol (acetaminophen) overdose] or because of the accumulation of a
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drug with a prolonged half-life (e.g. amiodarone), the measurement of circulating drug levels may be valuable in confirming diagnosis. The other situation where diagnostic tests may confirm clinical suspicion is when idiosyncratic hepatotoxicity arises via an immunologicallymediated mechanism (e.g. liver damage caused in susceptible individuals because they develop antibodies to a drug-related neoantigenj."> For a limited number of drugs, e.g. halothane.i" tienilic acid,217 rx-methyl dopa,2IB aromatic anticonvulsants such as phenytoin.l'? iproniazid.P? imipramine-" and erythromycin derivatives.F' specific antibodies can be detected in research assays performed in specialized units.
CONCLUSION
Although defining the cause of the liver disease is essential for initiating treatment, establishing its extent and the presence of associated complications has both prognostic and management consequences. Despite the plethora of newer tests, no single investigation establishes that a patient with liver disease has cirrhosis, portal hypertension and shunting or oesophageal varices-all of which may affect life expectancy significantly. Tests have been proposed for assessing these complications, such as the clearance of an oral testosterone load 223 or ursodeoxycholic acid,224 but their specificity is poorly characterized and an association with the general features of chronic liver disease is perhaps more likely." At the District General Hospital to which patients may first be referred following initial investigations by their general practitioner, there is an increasing demand for some of the newer diagnostic, prognostic and quantitative tests described above. Although their availability will be determined by both local specialist interest and specific laboratory expertise, certain tests emerge as being powerful adjuncts to the standard simple liver function tests. Their use will not only speed diagnosis but will also clarify referral and treatment options. Among the diagnostic tests of potential value are those for viral hepatitis C, anti-mitochondrial antibody in PBC, CA 19-9 for cholestasis, CDT for alcohol related liver disease and caeruloplasmin for Wilson disease and PSC. Although the methodology for molecular biology techniques is becoming increasingly simple with the advent of PCR and the ARMS method, there is still a need for expertise in the interpretation of the tests which at present probably limits their applicability in the non-specialist centre.
Of the laboratory tests which are prognostically useful, the MEGX test of hepatocellular activity is the most easily performed in nonspecialist laboratories. However, the MEGX test is likely to be most useful if performed serially because normal values fall within a relatively wide range depending on gender and drug ingestion. GST-rx is an assay with the greatest potential for widespread application, for detecting liver injury, but its clinical utility must await a more intensive validation.
In this review we have attempted to highlight many of the newer tests in the field of hepatology which the clinical chemist may encounter directly or via a physician with interests in hepatology. Whilst many of these will never cross the bridge from purely research tools to routine use, some of the tests indicated above, have begun to make the transition and others, possibly the markers of fibrosis, may do so in the future. The clinical chemist should be aware of the potential usefulness and limitations of such tests for the future. 37 
